Psychedelics FDA gives another one of Filament Health’s psilocybin trials green light The news follows the agency approving a Phase 2 study on PEX010 for different indications in April Rowan DunneJuly 7, 2025
Psychedelics Filament Health secures investment to remedy concerning financial position In year-end results, the psychedelics company reported a net loss of nearly C$5 million and a sharp drop in revenue Rowan DunneApril 4, 2025